View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 4, 2020

CEPI to fund Clover’s Covid-19 vaccine development

The Coalition for Epidemic Preparedness Innovations (CEPI) has extended its partnership to fund the development of Sichuan Clover Biopharmaceuticals’ protein-based S-Trimer Covid-19 vaccine candidate.

The Coalition for Epidemic Preparedness Innovations (CEPI) has extended its partnership to fund the development of Sichuan Clover Biopharmaceuticals’ protein-based S-Trimer Covid-19 vaccine candidate.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Clover’s S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate, which uses the Trimer-Tag technology.

Funding will be made through licensure, including a global Phase II / III efficacy clinical trial set to start before the end of this year.

CEPI’s total investment in the vaccine candidate will be up to $328m, which includes previously announced commitments of $69.5m.

In April, CEPI signed an agreement with Clover to support the development of the vaccine candidate.

CEPI CEO Dr Richard Hatchett said: “CEPI’s expanded investment will fund critical late-stage clinical trials to establish the efficacy of the vaccine, in parallel to scaling up the manufacturing process with the goal of making potentially hundreds of millions of doses of this vaccine available to those who need it through COVAX, if it is proven to be safe and effective.”

The previous funds aided Clover in the preclinical studies and Phase I clinical trials, preparations for the global pivotal Phase II / III efficacy study and initial manufacturing scale-up activities.

Preclinical and preliminary Phase I data showed that S-Trimer remains well-tolerated and produces strong neutralising antibody and Th1-biased cell-mediated immune responses.

With Clover’s successful early-stage clinical development of the vaccine candidate, CEPI decided to expand the partnership.

The Phase II / III trial plans to yield the necessary safety and efficacy data needed to support the licensure of the vaccine candidate.

Furthermore, CEPI will fund additional clinical studies in special populations including people with autoimmune conditions, immunocompromised individuals, pregnant women and children.

The programme will scale up the manufacturing process to produce over one billion doses a year and build up vaccine inventory.

According to the deal between CEPI and Clover, if safe and effective, the vaccine will be available for procurement and allocation through the COVAX Facility.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology